Cancer Research 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 6033-6037, December 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lew, Y. S.
Right arrow Articles by Kim, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lew, Y. S.
Right arrow Articles by Kim, J. H.
[Cancer Research 59, 6033-6037, December 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Arsenic Trioxide Causes Selective Necrosis in Solid Murine Tumors by Vascular Shutdown1

Young S. Lew2, Stephen L. Brown, Robert J. Griffin, Chang W. Song and Jae Ho Kim

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202 [Y. S. L., S. L. B., J. H. K.] and Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School, Minneapolis, Minnesota 55455 [R. J. G., C. W. S.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
To investigate the antitumor action of arsenic trioxide in solid tumors, we carried out quantitative tumor perfusion studies, using locally advanced methylcholanthrene-induced fibrosarcoma grown in BALB/c mice. The tumor perfusion studies were assessed by two separate methods: 99mTc clearance and 86Rb uptake. A single administration of arsenic trioxide (10 mg/kg i.p.) produced a preferential vascular shutdown in the tumor tissue at 2 and 6 h, leading to massive necrosis in the central part of the tumor. The phenomenon was repeatable at intervals of weekly administration of the drug in the same tumor. Normal skin, muscle, and kidney were relatively unaffected by arsenic trioxide. These results suggest that the drug may be investigated as an adjunct to the standard cancer therapeutic modalities.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Arsenic compounds have been used in traditional medicine in many countries for >1000 years. Approximately 100 years ago, Western medicine adopted some of these compounds, used them widely (1) , and subsequently abandoned them because of their toxic and oncogenic effects after chronic exposure. Arsenic compounds have received renewed attention in recent years following clinical observations of their effect on APL.3 In 1996, a group at Shanghai Institute of Hematology in China reported that As2O3 was an effective agent against APL even in patients who relapsed after retinoic acid-induced remission (2) . The rate of clinically complete remission with As2O3 treatment was >80% without obvious acute toxicity, including bone marrow suppression. These spectacular clinical observations, confirmed by others (3, 4, 5) , initiated investigations into the molecular mechanisms of As2O3-induced cell death.

It has been documented that arsenic can induce apoptosis in leukemic cells by activating apoptotic pathways (5 , 6) . However, the primary target of arsenic-induced cytotoxicity remains unknown. Trivalent arsenicals are regarded primarily as sulfhydryl reagents at the biochemical level. As2O3 inhibits many enzymes by reacting with biological ligands containing available sulfhydryl groups. Among them, arsenic targets vicinal thiol groups in tubulin with a high specificity (7) . We postulated that As2O3 may have an antivascular effect on solid tumors because tubulin has been shown to be a primary target for other antitumor and antivascular agents, such as colchicine (8) , flavone acetic acid (9) , and combretastatin-A4 (10) . We report the first in vivo observation demonstrating the antivascular effect of As2O3 in well-established murine solid tumors.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Mice, Tumors, and Compounds
The murine tumor line used was Meth-A in BALB/c mice (11) . Male mice, 6–8 weeks of age weighing 20–25 g were obtained from the Charles River Laboratories (Portage, MI). Meth-A cells were maintained by serial i.p. passage in syngeneic mice. For tumor implantation, Meth-A cells from ascitic fluid were collected between days 7 and 10 after cell implantation and washed twice with MEM medium. Approximately 1 x 105 viable Meth-A cells were inoculated into the skin of the right upper abdominal quadrant of the mouse. All experiments were carried out with intradermal tumors except for rubidium-uptake studies, which used s.c. tumors grown in the right rear leg of the mice.

As2O3 purchased from Sigma Chemical (St. Louis, MO) was dissolved in H2O by continuous stirring. As2O3 was kept at 4°C as a stock solution. Dilution was made with 0.9% NaCl to a final concentration of 0.5 mg/ml As2O3. Dextrose was added to a final concentration of 5% to minimize acute arsenic toxicity (12) .

Gross Morphology and Histopathology
Gross morphological changes were followed up to 48 h after a single injection of As2O3 (10 mg/kg i.p.). At selected time points, tumors were excised and histopathological examinations were performed. Tumor tissues from different groups were fixed in 10% neutral formalin and processed in paraffin wax. Sections (4 µm thick) were stained with H&E and assessed microscopically to investigate the temporal effect of As2O3.

Inhibition of Tumor Growth
Mice, typically five per group, with mean tumor diameters of 12.0 ± 1.0 mm were used in treatment or control studies. As2O3 was administered i.p. in doses of 10 mg/kg once a week for the duration of the experiment, starting 13 days after tumor inoculation. The same volume of normal saline with 5% dextrose was given to the control group. Tumor volume was assessed three times a week. Tumors were measured with a caliper, and tumor volumes were calculated assuming cylindrical growth using the formula a/2 x b/2 x h x {pi}, where a, b, and h are the minor and major dimensions and height, respectively. No attempt was made to correct the tumor volume measurement for the area of central necrosis.

Blood Perfusion Measurement
Two methods, technetium clearance and rubidium uptake, were used to assess the antivascular effect of a single injection of As2O3 (10 mg/kg i.p.). Both methods have been described in detail elsewhere (13 , 14) .

99mTc Clearance.
Clearance measurements were performed as described previously (13) . Briefly, mice were anesthetized with a 60 mg/kg i.p. injection of sodium pentobarbital and were immobilized using a jig that did not restrict blood flow to the tissue of interest. Technetium bound as sodium pertechnetate, Na99mTcO4 (typical activity, 6 µCi/ml), was injected directly into the central area of the intradermal tumor 10 min after the pentobarbital injection. A total volume of 10 µl was deposited, using a 29-gauge needle. Radioactivity was measured and recorded every 10 s, 200 times, using a multichannel scintillation counter (AccuSpec; Canberra Industries, Meriden, CT) interfaced with a personal computer. Raw data were corrected for the physical decay of technetium (6 h) and fit to a single exponential decay constant. No attempt to measure the partition coefficient was made, and the results are reported as clearance rate, not blood perfusion. The clearance rate was measured in each mouse before and 2, 6, and 24 h after arsenic treatment. Six tumor bearing mice with 12.0 ± 1.0 mm mean diameter tumors were used to study the effect of As2O3 on tumor clearance rate at each time point. Control experiments included clearance rate measurements in normal skin after As2O3 and also in untreated control tumors.

86Rb Uptake.
Changes in blood perfusion were measured in mouse tissue, using the rubidium uptake method (14) . The rubidium studies were performed using s.c. Meth-A tumors. The tumor site was not critical to the results because we obtained similar results with rubidium-uptake studies using intradermal tumors at selected time point. In all experiments, 5 µCi of 86RbCl in a 0.1-ml volume were injected through a tail vein after anesthesia with 100 mg/kg ketamine and 10 mg/kg xylazine, and mice were sacrificed by cervical dislocation 60 s after injection. The tumors, kidney, skin, and muscle were excised and counted in a well-counter (1282 Comugamma Cs; Pharmacia LKB Nuclear Inc., Gaithersburg, MD). The ratio of radioactive counts from the tissue of interest to the counts in the standard 86Rb solution equivalent to the total 86Rb activity injected multiplied by 100 gives the percentage of cardiac output to the tissue of interest. In this study, we did not attempt to measure absolute blood flow; relative blood perfusion values are presented. 86Rb uptake was measured before and 2, 6, and 24 h after arsenic treatment. At least 10 tumor-bearing mice were used for each time point. The results are reported as the percentage of 86Rb uptake per gram of tissue and plotted as a percentage of the control tissue.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Tolerance and Acute Effect of As2O3.
The toxicity of As2O3 was studied using the BALB/c mouse strain prior to initiating the tumor response studies. The approximate LD50 dose of an i.p. administration of As2O3 was 17 mg/kg. We used the maximally tolerated dose in this strain, which was 10 mg/kg. This dose induced reliable antitumor effects on locally advanced tumors and was well tolerated even in repeated administrations. Within 30 min after injection, mice showed signs and symptoms of acute toxicity, consisting of slurred motion, lethargy, and piloerection, but recovered within 6 h. No weight loss or other subacute toxicity was observed during the course of experiment.

Gross Morphological and Histopathological Changes.
Fig. 1ACitation illustrates gross tumor morphology before and after a single injection of the drug. As2O3 induced a pronounced central necrosis in the tumor, which was observed within 4 h and steadily progressed until at least 48 h. More than 70% of the tumor tissue underwent central necrosis, and the necrotic area formed a crust that became stony hard by 48 h. The tumor tissue under the crust was malleable. The peripheral zone of tumor tissue appeared unaffected. Tumor regrowth appeared to be initiated from the peripheral zone.



View larger version (133K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Morphological features of Meth-A tumors in BALB/c mice. A, sequential gross morphological changes before and after the administration of As2O3 (10 mg/kg i.p.). B–G, histological features of the tumors stained with H&E. B–D, x25 magnification; E–G, x400 magnification. V, nonnecrotic zone; N, necrotic zone.

 
The sequential histopathogical changes after drug treatment are shown in Fig. 1, B–GCitation . Untreated control tumors consist of undifferentiated round cells with evidence of focal necrosis and a thin layer of amorphous debris on the surface. Beginning at 8 h after the treatment, there were early signs of cell death. The majority of cells had separated from one another and rounded. Amorphous debris on the surface of the tumor became thicker. As early as 4 h, there were foci of vascular congestion and a minimal amount of interstitial hemorrhage continuing up to 8 h, but there was no evidence of intravascular coagulation or thrombosis. By 24 h, the central portion of the tumor became uniformly necrotic. Most of necrotic cells showed faint cytoplasmic staining and condensed, pyknotic nuclei. The peripheral area of the tumor was unaffected, with a well-demarcated interface between the viable and necrotic tissues. This phenomenon became more pronounced by 48 h.

Tumor Growth Delay.
Fig. 2Citation shows changes in the tumor volume as a function of time after a weekly administration of the drug. Immediately after the drug was administered, the tumor ceased to grow for ~2 days and then resumed growing. The regrowth was always seen from the periphery of the tumor. After administration of a second dose of the drug, tumor growth stopped for ~2 days, after which the tumor continued growing. A similar growth inhibitory pattern was observed after a third dose of the drug.



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Effect of As2O3 on the growth of Meth-A tumors in BALB/c mice. {circ}, untreated control group (vehicle only); •, As2O3 group, 10 mg/kg i.p. The arrowheads indicate the times of As2O3 administration. Data are the means of five animals per group. Bars, SE.

 
Effect of As2O3 on Regional Blood Perfusion in Tumor Tissue and Various Organs.
Fig. 3Citation shows the 99mTc clearance rate and 86Rb uptake as a function of time after a single administration of As2O3.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Effect of As2O3 (10 mg/kg) on the blood perfusion in Meth-A tumors in the BALB/c mice measured by 86Rb uptake and 99mTc clearance. Each point represents the mean of >10 mice for the rubidium uptake and 6 mice for 99mTc clearance. Bars, SE.

 
Clearance.
In the absence of As2O3, technetium cleared from the tumor site rapidly. The initial half-time of clearance was ~8–9 min, and this clearance rate did not change with subsequent injections even with seven repeat injections in the same area (data not shown). In contrast, the rate of technetium clearance was markedly reduced by the administration of As2O3 and remained low at 24 h, consistent with morphological observations.

Technetium clearance was 4.94 ± 1.53 h-1 before treatment and 2.57 ± 1.70, 0.58 ± 0.35, and 0.18 ± 0.09 h-1 at 2, 6, and 24 h after treatment, respectively. The calculated percentages relative to the control tumor were 52.1 ± 35.5, 11.6 ± 7.1, and 3.9 ± 1.8% of the control at 2, 6, and 24 h, respectively.

Uptake.
Rubidium uptake in Meth-A tumors showed that a significant decrease in tumor blood perfusion occurred at 2 and 6 h after As2O3 injection and that tumor blood perfusion had recovered by 24 h. Rubidium uptake was 1.50 ± 0.21%/g tissue before treatment, and it decreased to 0.20 ± 0.07, 0.30 ± 0.08, and 1.0 ± 0.20%/g tissue at 2, 6, and 24 h after treatment, respectively. The calculated percentage relative to control tumor blood perfusion was 16.4 ± 5.0, 20.5 ± 5.2, and 64.3 ± 13.3% of the control at 2, 6, and 24 h respectively. The data of 2 and 6 h after the drug treatment were similar to the trends for the clearance rate. The uptake data at 24 h were inconsistent with both technetium clearance and morphological observation (see "Discussion"). Similar trends in uptake were observed in two other tumor lines studied (FSaII in C3H mice and SCK in A/J mice; data not shown).

Fig. 4Citation illustrates the effect of As2O3 (10 mg/kg) on rubidium uptake in the kidney, skin, and leg muscle measured at the same time as the measurement in the tumor. Blood perfusion in the skin and muscle was not changed significantly compared with control values. The maximum reduction of blood perfusion in normal tissues was that of the kidney at 2 h after As2O3 (60.0 ± 5.5% of control). The reduction in blood perfusion reduction to the tumor was much greater than that in the normal tissues studied.



View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Changes in blood perfusion as a function of time in normal tissues and Meth-A tumor measured by 86Rb uptake. Values are the means of >10 mice at each time point.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
The data clearly demonstrate that As2O3 induces a prompt selective vascular shut down leading to massive central necrosis in Meth-A sarcoma grown in BALB/c mice. The profound tumor response occurred at a dosage of As2O3 that was well tolerated even in repeated administrations. The phenomenon was repeatable on subsequent administration on the same tumor.

Two different methods of blood perfusion measurements gave complementary information. Technetium clearance, which allows multiple measurements in the same tumor, demonstrated a decreased clearance rate with increasing time after As2O3 treatment. This finding corresponded well with the morphological findings. Rubidium uptake, a single measurement in different animals, yielded decreased blood perfusion relative to controls up to 6 h after As2O3 treatment, with some recovery at 24 h. Further analysis of the perfusion data at the 24-h time point showed that perfusion in half of the group of tumors (n = 6 of 14) remained low (mean ± SE, 24.4 ± 10.9% of the control tumor) and that perfusion in the other tumors (n = 8) recovered to near control values (94.2 ± 46.1%). Separate uptake studies with intradermal Meth-A tumors showed results similar to the results for the s.c. tumors. When rubidium activity was assessed from the central and peripheral parts of the tumor separately, the central part of the tumors had a lower uptake than the tumor periphery (37.6 ± 25.1% versus 82.2 ± 53.3%). These data indicate that the discrepancy between technetium clearance and rubidium uptake could be explained by the rubidium activity in the peripheral zone of the tumor. Regardless of the 24-h data, As2O3 treatment causes a rapid, selective shut down of tumor blood perfusion and induces massive necrosis in the central part of the tumor.

Several other antitumor agents, including combretastatin A-4 (10) , colchicine (8) , flavone acetic acid (9) and hydralazine (15) , have been shown to have their primary effects on tumor vasculature. Their effects are characterized by massive vascular shut down in the central region of the tumor. Flavone acetic acid, hydralazine, and colchicine are either ineffective or toxic in species other than mice. Combretastatin A-4 and new flavone acetic acid derivatives have shown promise in overcoming these past problems. Similarly, As2O3 has been used in humans for many years, and preliminary studies on rats in this laboratory indicate that its antitumor effects may not be species specific.4

The underlying mechanisms of vascular shut down and central necrosis are not easily explained by our current knowledge of the known biological effects of As2O3. However, several possible scenarios are being entertained to illustrate this phenomenon. One possible mechanism is that As2O3 can induce selective endothelial cell injury, resulting in vascular shut down to tumor tissue. This mechanism is based on the observation that As2O3 is a noncompetitive inhibitor of GTP binding to tubulin (7) . Combretastatin A-4 affects normal microtuble function and has been shown to have a greater toxicity toward endothelial cells compared with tumor cells in vitro and induces selective vascular shut down in P22 rat carcinosarcoma in vivo (10) . Another tubulin-binding agent, colchicine, produced hemorrhagic necrosis in experimental tumors (8) .

Another possible scenario is tumor necrosis factor-mediated vascular shut down, because the gross observation after As2O3 treatment is similar to that seen with endotoxin-induced necrosis. The evidence is strengthened by the observation that cultured human keratinocytes overexpress tumor necrosis factor mRNA after arsenic exposure (16) .

Apoptosis or/and necrosis represents a third possible scenario. As2O3 triggers apoptosis in APL cells by degrading promyelocytic leukemia/retinoic acid receptor-{alpha} fusion protein (6 , 17) , but it also induces apoptosis in other hematological malignancies and several solid tumor cells in vitro (7 , 18 , 19) at a lower concentration (0.5–5 µM). At higher concentrations (>5 µM), As2O3 causes acute necrosis in various cell lines (7) . In this scenario, we can speculate massive apoptosis or/and necrosis in the central area of the tumor after As2O3 exposure.

The decrease in blood perfusion in the kidney and tumors observed with rubidium uptake suggests a systemic effect of As2O3. Changes in blood pressure measured using plethysmography on the tail revealed that the systolic pressure dropped to 50% of the original pressure 1 h after As2O3 injection (data not shown), remained low for ~1 h, and recovered gradually to near normal levels by 6 h. As2O3-induced systemic hypotension in the presence of high tumor interstitial fluid pressure, especially in the central area of the tumor (20) , may be considered a contributing factor in inducing a vascular shut down.

We currently are investigating these possible scenarios, but most of our preliminary data do not unequivocally confirm any of the possible scenarios. Nonetheless, the present findings that As2O3 induces a rapid tumor mass reduction with a viable, presumably well-oxygenated peripheral zone of the tumor may provide an opportunity to combine this approach with standard cancer therapy that includes radiation and cytotoxic agents.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by NIH Grants NIH-CA59542, NIH-CA44114, and DAMD17-99-9215. Back

2 To whom requests for reprints should be addressed, at Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202 Fax: (313) 916-3235; E-mail: younglew{at}yahoo.com Back

3 The abbreviations used are: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; Meth-A, methylcholanthrene-induced fibrosarcoma. Back

4 Y. S. Lew et al., unpublished results. Back

Received 9/13/99. Accepted 10/29/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Sears D. A. History of the treatment of chronic myelocytic leukemia. Am. J. Med. Sci., 296: 85-86, 1988.[Medline]
  2. Shen Z. X., Chen G. Q., Ni J. H., Li X. S., Xong S. M., Qiu Q. Y., Zhu J., Tang W., Sun G. L., Yang K. Q., Chen Y., Zhou L., Fang Z. W., Wang Y. T., Ma J., Zhang P., Zhang T. D., Chen S. J., Chen Z., Wang Z. Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.[Abstract/Free Full Text]
  3. Westervelt P., Pollock J., Haug J., Ley T. J., DiPersio J. F. Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia. Blood, 90(Suppl. 1): 249b 1997.
  4. Matthews J. H., Tompkins K., Hasegawa W., Brander M. J., Rapson D. A., Galbraith P. R. Successful arsenic therapy in relapsed acute promyelocytic leukemia resistant to all-trans retinoic acid. Proc. Am. Soc. Clin. Oncol., 17: 122 1998.
  5. Soignet S. L., Maslak P., Wang Z. G., Jhanwar S., Calleja E., Dardashti L. J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D. A., Pandolfi P. P., Warrell R. P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998.[Abstract/Free Full Text]
  6. Chen G. Q., Zhu J., Shi X. G., Ni J. H., Zhong H. J., Si G. Y., Jin X. L., Tang W., Li X. S., Xong S. M., Shen Z. X., Sun G. L., Ma J., Zhang P., Zhang T. D., Gazin C., Naoe T., Chen S. J., Wang Z. Y., Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR {alpha}/PML proteins. Blood, 88: 1052-1061, 1996.[Abstract/Free Full Text]
  7. Li Y. M., Broome J. D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res., 59: 776-780, 1999.[Abstract/Free Full Text]
  8. Ludford R. J. Colchicine in the experimental chemotherapy of cancer. J. Natl. Cancer Inst., 6: 89-101, 1945.
  9. Zwi L. J., Baguley B. C., Gavin J. B., Wilson W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J. Natl. Cancer Inst., 81: 1005-1013, 1989.[Abstract/Free Full Text]
  10. Tozer G. M., Prise V. E., Wilson J., Locke R. J., Vojnovic B., Stratford M. R., Dennis M. F., Chaplin D. J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res., 59: 1626-1634, 1999.[Abstract/Free Full Text]
  11. Ryu S., Brown S. L., Kolozsvary A., Kim J. H. Increased tumour response of a murine fibrosarcoma to low temperature hyperthermia and low dose rate brachytherapy. Int. J. Hyperthermia, 12: 635-643, 1996.[Medline]
  12. Reichl F. X., Kreppel H., Szinicz L., Fichtl B., Forth W. Reduction of arsenic trioxide toxicity in mice by repeated treatment with glucose. Arch. Toxicol. Suppl., 14: 225-227, 1991.[Medline]
  13. Brown S. L., Hunt J. W., Hill R. P. A comparison of the rate of clearance of xenon (133Xe) and pertechnetate ion (99mTcO4-) in murine tumors and normal leg muscles. Nucl. Med. Biol., 15: 381-390, 1988.
  14. Song C. W., Patten M. S., Chelstrom L. M., Rhee J. G., Levitt S. H. Effect of multiple heatings on the blood flow in RIF-1 tumours, skin and muscle of C3H mice. Int. J. Hyperthermia, 3: 535-545, 1987.[Medline]
  15. Lin J. C., Song C. W. Effects of hydralazine on the blood flow in RIF-1 tumors and normal tissues of mice. Radiat. Res., 124: 171-177, 1990.[Medline]
  16. Germolec D. R., Yoshida T., Gaido K., Wilmer J. L., Simeonova P. P., Kayama F., Burleson F., Dong W., Lange R. W., Luster M. I. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol., 141: 308-318, 1996.[Medline]
  17. Shao W., Fanelli M., Ferrara F. F., Riccioni R., Rosenauer A., Davison K., Lamph W. W., Waxman S., Pelicci P. G., Lo Coco F., Avvisati G., Testa U., Peschle C., Gambacorti-Passerini C., Nervi C., Miller W. H., Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR {alpha} protein in acute promyelocytic leukemia cells. J. Natl Cancer Inst., 90: 124-133, 1998.[Abstract/Free Full Text]
  18. Zhu X. H., Shen Y. L., Jing Y. K., Cai X., Jia P. M., Huang Y., Tang W., Shi G. Y., Sun Y. P., Dai J., Wang Z. Y., Chen S. J., Zhang T. D., Waxman S., Chen Z., Chen G. Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst., 91: 772-778, 1999.[Abstract/Free Full Text]
  19. Rousselot P., Labaume S., Marolleau J. P., Larghero J., Noguera M. H., Brouet J. C., Fermand J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res., 59: 1041-1048, 1999.[Abstract/Free Full Text]
  20. Boucher Y., Baxter L. T., Jain R. K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res., 50: 4478-4484, 1990.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lew, Y. S.
Right arrow Articles by Kim, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lew, Y. S.
Right arrow Articles by Kim, J. H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online